In addition, we show for the first time that B cells from multiple sclerosis patients treated with alemtuzumab have increased anti-proliferative function (Figure 2C), that this correlates with IL-10 secretion (Figure 2E), and that increases in regulatory B cells correlate with increases in regulatory T cells (Figures 3E, F). This evidence concerns the gene IL10 and multiple sclerosis.